Hematologist Vijay Sankaran receives Boston Children’s Hospital Rising Star Award

Awards-8

Before an audience of several hundred luncheon attendees, physician-scientist Vijay G. Sankaran, MD, PhD, received Boston Children’s Hospital’s 2015 Rising Star Award — recognizing the outstanding achievements of an up-and-coming innovator under the age of 45 in pediatric health care.

Sankaran, a board-certified pediatric hematologist/oncologist with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, conducts innovative research on red blood cell disorders such as Diamond-Blackfan anemia, sickle cell disease and thalassemia.

The Rising Star Award and companion Lifetime Impact Award ceremony were held at the hospital’s Global Pediatric Innovation Summit + Awards on November 10.

“Vijay’s work exemplifies why the Rising Star was created — he’s a shining example of the fact that the best in pediatric innovation is yet to come,” said Boston Children’s Hospital President and CEO Sandra L. Fenwick. “What makes his work with blood stem cells so significant isn’t the impact that it could have on children at Boston Children’s Hospital; it’s the impact it could have on patients of all ages, worldwide.”

Sankaran, who received his doctorate and medical degree from Harvard Medical School in 2009 and 2010, simultaneously pursued medical and postdoctoral research training at Boston Children’s Hospital, Boston Medical Center, the Whitehead Institute for Biomedical Research and the Broad Institute.

In 2014, Sankaran established his laboratory at Dana-Farber/Boston Children’s and was appointed an assistant professor of pediatrics at Harvard Medical School.

In an earlier interview, Sankaran shared the pivotal moment when his concentration turned to blood cell production and research, and how many pioneers influenced his research path.

“I vividly remember going to a symposium on blood cell production held many years ago when I was a first year medical student. A number of pioneers in the blood cell field were there, including Stuart Orkin, Leonard Zon, Irving Weissman and others,” Sankaran told Boston Children’s. “The great work being done in animal models of blood cell production, such as mice or zebrafish, inspired me to explore what more could be done.”

Sankaran’s mentor and 2015 Lifetime Impact Award recipient Stuart H. Orkin, MD, of Dana-Farber/Boston Children’s, says Sankaran is destined for innovative greatness.

Awards_6
L to R: Sandra L. Fenwick, Stuart Orkin, MD, and Vijay Sankaran, MD, PhD

“[Vijay] has already established a vibrant laboratory that is using human genetics to provide clues to the defects and pathophysiology of hematologic disorders,” wrote Orkin in support of Sankaran’s nomination. “It is hard to conceive of another young pediatric investigator who has accomplished so much in such a short time and is poised to make truly innovative discoveries going forward.”

Sankaran’s accomplishments include establishing an ambitious platform of research focused on the genetics, genomics, cellular biology and physiology of red blood cell development and red blood cell disorders. Over a period of four years, Sankaran combined human genetics and whole genome mapping to identify the molecular switch BCL11A as a possible treatment target for sickle cell disease and thalassemia, diseases both related to hemoglobin mutations. His discoveries are fueling current efforts to affect the gene’s activity therapeutically using gene editing tools such as CRISPR.

In addition, Sankaran’s molecular research on Diamond-Blackfan anemia (DBA), a severe, congenital form of anemia, has directly resulted in a unified model of DBA biology that integrates seemingly conflicting genetic discoveries about the condition into a comprehensive explanation of its biochemical underpinnings.

Most recently, Sankaran’s laboratory found it could triple blood stem cells’ production of red blood cells by shutting off the gene SH2B3, a target identified by combing data from genome-wide association studies. The work, reported recently by TIME, could lead to better, cheaper methods of manufacturing red blood cells for transfusion and for use as drug delivery vehicles.

“Vijay is extremely unusual for a scientist at his career stage in that he can both conceptualize an entire field of investigation and define a focused set of studies that get to the heart of a difficult problem,” the Whitehead Institute’s Harvey Lodish, PhD, one of Sankaran’s mentors, wrote in seconding him for the award. “He is a physician-scientist who is expert in fields as diverse as human genetics and computational analysis of genetic and molecular data; he is also a skilled diagnostician and is already considered a world expert in hematologic diseases.”

Watch video highlights of the 2015 Global Pediatric Innovation Summit + Awards.